Technical Analysis for ASND - Ascendis Pharma A/S
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical ASND trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Multiple of Ten Bearish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | -0.95% | |
| Slingshot Bullish | Bullish Swing Setup | -0.95% | |
| NR7 | Range Contraction | -0.95% | |
| Multiple of Ten Bullish | Other | -0.95% | |
| Up 3 Days in a Row | Strength | -0.95% | |
| Up 4 Days in a Row | Strength | -0.95% | |
| Shooting Star Candlestick | Bearish | -0.05% | |
| Lizard Bearish | Bearish Day Trade Setup | -0.05% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/18/2019
- Sector: Healthcare
- Industry: Biotechnology
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Biotechnology Life Sciences Disease Diabetes Hormones Pulmonary Arterial Hypertension Peptide Hormones Treatment Of Diabetes Breakthrough Therapy Genentech Recombinant Proteins Treprostinil
Biotechnology Life Sciences Disease Diabetes Hormones Pulmonary Arterial Hypertension Peptide Hormones Treatment Of Diabetes Breakthrough Therapy Genentech Recombinant Proteins Treprostinil
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 142.94 |
| 52 Week Low | 66.115 |
| Average Volume | 262,963 |
| 200-Day Moving Average | 115.51 |
| 50-Day Moving Average | 122.63 |
| 20-Day Moving Average | 135.94 |
| 10-Day Moving Average | 137.93 |
| Average True Range | 4.69 |
| ADX | 34.27 |
| +DI | 28.11 |
| -DI | 15.12 |
| Chandelier Exit (Long, 3 ATRs ) | 128.88 |
| Chandelier Exit (Short, 3 ATRs ) | 131.59 |
| Upper Bollinger Band | 144.34 |
| Lower Bollinger Band | 127.55 |
| Percent B (%b) | 0.69 |
| BandWidth | 12.35 |
| MACD Line | 5.21 |
| MACD Signal Line | 5.68 |
| MACD Histogram | -0.4729 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 146.95 | ||||
| Resistance 3 (R3) | 147.00 | 144.44 | 145.64 | ||
| Resistance 2 (R2) | 144.44 | 142.45 | 144.41 | 145.21 | |
| Resistance 1 (R1) | 141.78 | 141.22 | 140.51 | 141.74 | 144.78 |
| Pivot Point | 139.23 | 139.23 | 138.59 | 139.20 | 139.23 |
| Support 1 (S1) | 136.57 | 137.24 | 135.29 | 136.52 | 133.48 |
| Support 2 (S2) | 134.02 | 136.01 | 133.99 | 133.05 | |
| Support 3 (S3) | 131.36 | 134.02 | 132.62 | ||
| Support 4 (S4) | 131.31 |
